SkadBytes Podcast | AI Regulation: EU and UK Update and What It Means in Practice
The Briefing: Frida Kahlo vs. The 11th Circuit - A Warning for IP Owners Everywhere
Navigating ICE’s Updated I-9 Audit Guidelines: What Employers Need to Know
At the Intersection of Biotech and AI with Janice Vatland
Podcast - De genérica a icónica: El glow up de una marca
JONES DAY PRESENTS®: Cross-Border Trade Secret Litigation in the U.S. Courts
How Did James Bond Spark a 50-Year Legal War Over Who Owns 007? — No Infringement Intended Podcast
Episode 406 -- AI Risks and Compliance: Building a Governance Framework
The Briefing: Taylor Swift, Trademark Law, and the Fight Over ‘Life of a Showgirl’
DOJ’s Bulk Sensitive Data Transfer Rule: Key Insights for Health Care Compliance Teams – Diagnosing Health Care
SBR-Author’s Podcast: Bribery Beyond Borders: The Hidden History and Future of the FCPA with Severin Wirz
'Urgent National Action to Save College Sports': Trump’s NIL Playbook — Highway to NIL Podcast
March Madness or Trademark Madness? The NCAA v. DraftKings Lawsuit
Protecting Your Products and Brand Online
Lemon Pound Cake and the First Amendment
Episode 402: Paul Allen: The Promise of AI, Governance and Public Trust
Michele Moresco on the Transformational Potential of Photonics
Subject Matter Eligibility Challenges in Post-Grant Proceedings — Patents: Post-Grant Podcast
The Briefing: Vampires, Love Triangles, but No Infringement
Non-Competes in 2026: FTC Signals Major Policy Shift - Employment Law This Week® - Spilling Secrets Podcast
For venture capital investors in the life sciences sector, intellectual property (IP) is not merely a legal checklist item, it can be a primary determinant of company value, competitive insulation, and exit options....more
Ever eager to retain control over her masters and ensure that she “never goes out of style,” Taylor Swift is the latest public figure looking toward registration of sensory trademarks to protect her name and likeness in a...more
While the Supreme Court established a rather definitive standard (“reasonable certainty by a person having ordinary skill in the art”) for determining indefiniteness under 35 U.S.C. § 112(b) in Nautilus, Inc. v. Biosig...more
Denosumab Challenged Claim Types in Litigation: Claims are counted in each litigation, so claims from the same patent challenged in multiple litigations are counted more than once. Within each litigation a claim is counted...more
Innovation today rarely sits within a single building or even a single country. Multinational teams collaborate across borders, and ideas move faster than the rules designed to regulate them. Yet when it comes to patent...more
Enviro Tech Chem. Servs., Inc. v. Safe Foods Corp., Appeal No. 2024-2160 (Fed. Cir. May 4, 2026) In its only precedential patent opinion last week, the Federal Circuit affirmed a district court’s determination that asserted...more
Tocilizumab Challenged Claim Types in IPRs: Claims are counted in each IPR, so claims from the same patent challenged in multiple IPRs are counted more than once. Within each IPR, claims are counted only once, whether they...more
As previously reported, litigation between Johnson & Johnson and Janssen (“J&J”) and Samsung Bioepis (“Samsung”) involving Samsung’s Stelara biosimilar, PYZCHIVA (ustekinumab-ttwe) (previously known as SB17), was resolved via...more
Etanercept Challenged Claim Types in IPR and Litigation: Claims include those challenged in litigations and IPRs. Claims are counted in each litigation and IPR, so claims from the same patent challenged in multiple...more
On April 24, Taylor Swift’s company, TAS Rights Management, filed three new trademark applications with the US Patent and Trademark Office (USPTO) in what appears to be an effort to safeguard her identity against the rising...more
The number of venues for enforcing standard essential patents (SEPs) continues to increase all over the world. Here, we explain the main drivers behind why patent owners may want to choose the U.S. International Trade...more
Trastuzumab Challenged Claim Types in IPR and Litigation: Claims include those challenged in litigations and IPRs. Claims are counted in each litigation and IPR, so claims from the same patent challenged in multiple...more
On April 30, 2026, the U.S. International Trade Commission proposed amendments to 19 C.F.R. Part 210 that would require all nongovernment parties in Section 337 Investigations to disclose entities with an ownership or...more
The Puma Supreme People’s Court case confirms that, where a design patent is challenged on the ground that it conflicts with earlier trademark rights, Chinese courts will assess the conflict by examining whether a design...more
Trade secret litigation often turns on fast-moving disputes over information, competition, and control. Each month, we highlight notable rulings, verdicts, and enforcement actions shaping trade secret risk and litigation...more
Key Takeaways - AI agents can harvest, synthesize, and exfiltrate trade secrets through more than a dozen evasion techniques that generate no conventional security alert....more
May 11, 2026 marks the tenth anniversary of the Defend Trade Secrets Act. The DTSA created a federal civil cause of action for trade secret misappropriation, giving companies across the country a powerful new tool to protect...more
Welcome to the latest issue of Insurance Insights, a gathering of notable legal developments and trends relevant to the insurance industry. In this issue, we cover five things to know about artificial intelligence, an...more
The saga of Joe Exotic has generated no shortage of legal drama. And a recent Tenth Circuit decision adds an important new chapter — one with significant implications for copyright holders and content creators alike across...more
In a Federal Register notice published May 6, the USPTO extended the program through May 6, 2028, with one principal change: the Board now aims to issue a decision within four months from the date the appeal enters the...more
Adalimumab Challenged Claim Types in IPR and Litigation: Claims include those challenged in litigations and IPRs. Claims are counted in each litigation and IPR, so claims from the same patent challenged in multiple...more
Intellectual property is one of the – if not the – greatest assets a business can own. Innovative companies need to carefully identify and protect their IP assets in order to maximize their value over their terms of...more
Rituximab Challenged Claim Types in IPR and Litigation: Claims include those challenged in litigations and IPRs. Claims are counted in each litigation and IPR, so claims from the same patent challenged in multiple...more
Biosimilar Litigations include litigations relating to biosimilar/follow-on products of CDER-listed reference products. Litigations between biosimilar applicants/manufacturers and reference product sponsors as well as...more
As covered in our prior alert, the USPTO’s new pre-order paper procedure allows a patent owner to file a 30-page paper within 30 days after being served with an ex parte reexamination (EPR) request filed with the Central...more